country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-19188

Copy Link Print Information

GL-331

GL-331 is a potent anti-cancer agent. GL-331 has demonstrated more efficacious anti-cancer activity in both the in vitro and in vivo lymphoma systems.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 127882-73-9
分子式: C₂₇H₂₄N₂O₉
分子量:520.49

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (274 KB)

GL-331 構造式

CAS 番号: 127882-73-9

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

GL-331 is a potent anti-cancer agent. GL-331 has demonstrated more efficacious anti-cancer activity in both the in vitro and in vivo lymphoma systems^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
1A9	ED₅₀	<1.6 μM Compound: 6	Effective dose of compound against replication of 1A9 cell line was evaluated Effective dose of compound against replication of 1A9 cell line was evaluated	[PMID: 15006408]
A549	ED₅₀	<0.1 μM Compound: 6	Effective dose of compound against replication of A549 cell line was evaluated Effective dose of compound against replication of A549 cell line was evaluated	[PMID: 15006408]
A549	IC₅₀	0.113 μg/mL Compound: GL-331	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 22658864]
A549	IC₅₀	15.8 nM Compound: Ref 34, Cpd 4	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
CAKI-1	ED₅₀	1.5 mM Compound: GL331	The compound was tested for tumor cell growth inhibitory activity against human renal cancer(CAKI-1) cell line The compound was tested for tumor cell growth inhibitory activity against human renal cancer(CAKI-1) cell line	[PMID: 10395485]
DU-145	IC₅₀	0.8 μg/mL Compound: GL-331	Cytotoxicity against human DU145 cells by SRB assay Cytotoxicity against human DU145 cells by SRB assay	[PMID: 22658864]
H9	EC₅₀	<0.00128 μM Compound: 15	Evaluation for anti-HIV activity using T cell line (H9). Evaluation for anti-HIV activity using T cell line (H9).	10.1016/S0960-894X(97)10108-1
H9	IC₅₀	0.07 μM Compound: 15	Cytotoxicity against H9 cell line Cytotoxicity against H9 cell line	10.1016/S0960-894X(97)10108-1
HCT-8	ED₅₀	1.6 μM Compound: 6	Effective dose of compound against replication of HCT-8 cell line was evaluated Effective dose of compound against replication of HCT-8 cell line was evaluated	[PMID: 15006408]
HCT-8	ED₅₀	8.5 mM Compound: GL331	The compound was tested for tumor cell growth inhibitory activity against human ileocecal carcinoma (HCT-8) cell line The compound was tested for tumor cell growth inhibitory activity against human ileocecal carcinoma (HCT-8) cell line	[PMID: 10395485]
HOS	ED₅₀	<1.6 μM Compound: 6	Effective dose of compound against replication of HOS cell line was evaluated Effective dose of compound against replication of HOS cell line was evaluated	[PMID: 15006408]
KB	ED₅₀	0.2 μg/mL Compound: 6	Dose required to cause reduction in human nasopharyngeal KB cancer cells after 3 days incubation Dose required to cause reduction in human nasopharyngeal KB cancer cells after 3 days incubation	[PMID: 15456257]
KB	ED₅₀	0.2 μg/mL Compound: 63, NSC-628679	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 20187635]
KB	ED₅₀	0.49 mM Compound: GL331	The compound was tested for tumor cell growth inhibitory activity against human nasopharynx carcinoma(KB) cell line. The compound was tested for tumor cell growth inhibitory activity against human nasopharynx carcinoma(KB) cell line.	[PMID: 10395485]
KB	ED₅₀	1.5 μM Compound: 4	Effective dose required for inhibition of KB-7d cell replication after 3 days of continuous treatment Effective dose required for inhibition of KB-7d cell replication after 3 days of continuous treatment	[PMID: 15125972]
KB	ED₅₀	1.5 μM Compound: 6	Effective dose of compound against replication of KB/7d cell line was evaluated Effective dose of compound against replication of KB/7d cell line was evaluated	[PMID: 15006408]
KB	ED₅₀	2 μg/mL Compound: 6	Dose required for reduction in human nasopharyngeal KB-7d cancer cells after 3 days incubation Dose required for reduction in human nasopharyngeal KB-7d cancer cells after 3 days incubation	[PMID: 15456257]
KB	ED₅₀	3.5 μM Compound: 6	Effective dose of compound against replication of KB cell line was evaluated Effective dose of compound against replication of KB cell line was evaluated	[PMID: 15006408]
KB	ED₅₀	4.1 μM Compound: 6	Effective dose of compound against replication of KB-Vin cell line was evaluated Effective dose of compound against replication of KB-Vin cell line was evaluated	[PMID: 15006408]
KB	IC₅₀	0.032 μM Compound: 1	Growth inhibitory activity (antiproliferative) against KB cell lines Growth inhibitory activity (antiproliferative) against KB cell lines	[PMID: 8691469]
KB	IC₅₀	0.49 μM Compound: 63, NSC-628679	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 20187635]
KB	IC₅₀	0.49 μM Compound: 15	Concentration required for 50% reduction in KB cell number after 3-day incubation Concentration required for 50% reduction in KB cell number after 3-day incubation	[PMID: 1312600]
KB	IC₅₀	0.49 μM Compound: 32	Concentration required for 50% reduction in KB cell number after 3-day incubation Concentration required for 50% reduction in KB cell number after 3-day incubation	[PMID: 1312601]
KB	IC₅₀	0.55 μM Compound: 1	Growth inhibitory activity (antiproliferative) against KB/7d cell lines Growth inhibitory activity (antiproliferative) against KB/7d cell lines	[PMID: 8691469]
KB	IC₅₀	0.819 μg/mL Compound: GL-331	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 22658864]
KB	IC₅₀	3 μM Compound: 63, NSC-628679	Cytotoxicity against human vincristine-resistant KB cells after 72 hrs by MTT assay Cytotoxicity against human vincristine-resistant KB cells after 72 hrs by MTT assay	[PMID: 20187635]
MCF7	ED₅₀	24.5 μM Compound: 6	Effective dose of compound against replication of MCF-7 cell line was evaluated Effective dose of compound against replication of MCF-7 cell line was evaluated	[PMID: 15006408]
MCF7	ED₅₀	28.5 mM Compound: GL331	The compound was tested for tumor cell growth inhibitory activity against human breast cancer (MCF-7) cell line. The compound was tested for tumor cell growth inhibitory activity against human breast cancer (MCF-7) cell line.	[PMID: 10395485]
MCF7	IC₅₀	15.8 nM Compound: Ref 34, Cpd 4	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
PC-3	ED₅₀	8.9 μM Compound: 6	Effective dose of compound against replication of PC-3 cell line was evaluated Effective dose of compound against replication of PC-3 cell line was evaluated	[PMID: 15006408]
PC-3	IC₅₀	15.8 nM Compound: Ref 34, Cpd 4	Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay	[PMID: 32992133]
SK-MEL-2	ED₅₀	16.5 mM Compound: GL331	The compound was tested for tumor cell growth inhibitory activity against human melanoma (SKMEL-2) cell line. The compound was tested for tumor cell growth inhibitory activity against human melanoma (SKMEL-2) cell line.	[PMID: 10395485]
SK-MEL-2	ED₅₀	3 μM Compound: 6	Effective dose of compound against replication of SK-MEL-2 cell line was evaluated Effective dose of compound against replication of SK-MEL-2 cell line was evaluated	[PMID: 15006408]
U-373MG ATCC	IC₅₀	1 nM Compound: 42; GL331	Inhibition of HIF-1alpha in human U373 cells Inhibition of HIF-1alpha in human U373 cells	[PMID: 30682255]
U-87MG ATCC	ED₅₀	5.5 μM Compound: 6	Effective dose of compound against replication of U87MG cell line was evaluated Effective dose of compound against replication of U87MG cell line was evaluated	[PMID: 15006408]

体外実験

GL-331 shows more efficacy than VP-16 (HY-13629) in killing cancer cells. GL-331 possesses more cell-killing activity even in MDR-1-overexpressing cell lines such as HCC36 and SW620. Its higher cytotoxicity can be attributed by the elevated ability to induce apoptotic cell death^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 127882-73-9
分子量 520.49
分子式 C₂₇H₂₄N₂O₉
SMILES

O=C1OC[C@]2([H])[C@H](NC3=CC=C([N+]([O-])=O)C=C3)C4=C(C=C5OCOC5=C4)[C@@H](C6=CC(OC)=C(O)C(OC)=C6)[C@]21[H]
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (274 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. You Y. Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents. Curr Pharm Des. 2005;11(13):1695-717. [Content Brief]

[2]. Huang TS, et al. A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharm Res. 1999 Jul;16(7):997-1002. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ